Pharmacogenomics Technology Market Report: Trends, Forecast and Competitive Analysis to 2030

Pharmacogenomics Technology Trends and Forecast

The future of the global pharmacogenomics technology market looks promising with opportunities in the oncology, neurological disorder, cardiovascular disease, immunological disorder, and infectious diseases market. The global pharmacogenomics technology market is expected to reach an estimated $12.4 billion by 2030 with a CAGR of 6.7% from 2024 to 2030. The major drivers for this market are significant progress in comprehending genetic differences in the field of genomics and their influence on medication responsiveness, growing need for individualized treatment owing to the increasing incidence of chronic illnesses, and the decrease in cost of genome sequencing and advances in technology.

A more than 150-page report is developed to help in your business decisions.

Pharmacogenomics Technology by Segment

The study includes a forecast for the global pharmacogenomics technology by technology, therapeutic area, and region.

Pharmacogenomics Technology Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

• PCR
• In-Situ Hybridization
• Immunohistochemistry
• Sequencing
• Others

Pharmacogenomics Technology Market by Therapeutic Area [Shipment Analysis by Value from 2018 to 2030]:

• Oncology
• Neurological Disorders
• Cardiovascular Disease
• Immunological Disorders
• Infectious Diseases
• Others

Pharmacogenomics Technology Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Pharmacogenomics Technology Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies pharmacogenomics technology companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the pharmacogenomics technology companies profiled in this report include-

• GE HealthCare
• Agilent Technologies
• F. Hoffmann-La Roche
• FOUNDATION MEDICINE
• Thermo Fisher Scientific
• Leica Biosystems Nussloch
• Pfizer

Pharmacogenomics Technology Market Insights

Lucintel forecasts that PCR will remain the largest segment over the forecast period because it enables the amplification of particular DNA sequences, which makes it an essential tool for genotyping and determining genetic variants linked to medication response, and it is frequently used to find genetic alterations and single nucleotide polymorphisms (SNPs) that impact drug efficacy and metabolism.

North America will remain the largest region over the forecast period due to existence of prominent companies in this area, advantageous reimbursement rules, rise in awareness of the importance of early diagnosis for improved treatment, and a well-developed healthcare infrastructure in this area.

Features of the Global Pharmacogenomics Technology Market

Market Size Estimates: Pharmacogenomics technology market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Pharmacogenomics technology market size by technology, therapeutic area, and region in terms of value ($B).

Regional Analysis: Pharmacogenomics technology market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different technology, therapeutic area, and regions for the pharmacogenomics technology market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the pharmacogenomics technology market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the pharmacogenomics technology market size?

Answer: The global pharmacogenomics technology market is expected to reach an estimated $12.4 billion by 2030.

Q2. What is the growth forecast for pharmacogenomics technology market?

Answer: The global pharmacogenomics technology market is expected to grow with a CAGR of 6.7% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the pharmacogenomics technology market?

Answer: The major drivers for this market are significant progress in comprehending genetic differences in the field of genomics and their influence on medication responsiveness, growing need for individualized treatment owing to the increasing incidence of chronic illnesses, and the decrease in cost of genome sequencing and advances in technology.

Q4. What are the major segments for pharmacogenomics technology market?

Answer: The future of the global pharmacogenomics technology market looks promising with opportunities in the oncology, neurological disorder, cardiovascular disease, immunological disorder, and infectious diseases market.

Q5. Who are the key pharmacogenomics technology market companies?

Answer: Some of the key pharmacogenomics technology companies are as follows.

• GE HealthCare
• Agilent Technologies
• F. Hoffmann-La Roche
• FOUNDATION MEDICINE
• Thermo Fisher Scientific
• Leica Biosystems Nussloch
• Pfizer

Q6. Which pharmacogenomics technology market segment will be the largest in future?

Answer: Lucintel forecasts that PCR will remain the largest segment over the forecast period because it enables the amplification of particular DNA sequences, which makes it an essential tool for genotyping and determining genetic variants linked to medication response, and it is frequently used to find genetic alterations and single nucleotide polymorphisms (SNPs) that impact drug efficacy and metabolism.

Q7. In pharmacogenomics technology market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to existence of prominent companies in this area, advantageous reimbursement rules, rise in awareness of the importance of early diagnosis for improved treatment, and a well-developed healthcare infrastructure in this area.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the pharmacogenomics technology market by technology (PCR, in-situ hybridization, immunohistochemistry, sequencing, and others), therapeutic area (oncology, neurological disorders, cardiovascular disease, immunological disorders, infectious diseases, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?